Equities analysts expect Nabriva Therapeutics AG (NASDAQ:NBRV) to announce sales of $1.35 million for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Nabriva Therapeutics AG’s earnings. The highest sales estimate is $1.75 million and the lowest is $600,000.00. The company is scheduled to report its next quarterly earnings results on Wednesday, November 15th.
According to Zacks, analysts expect that Nabriva Therapeutics AG will report full year sales of $1.35 million for the current fiscal year, with estimates ranging from $3.48 million to $6.90 million. For the next year, analysts anticipate that the business will report sales of $6.15 million per share, with estimates ranging from $1.20 million to $9.50 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Nabriva Therapeutics AG.
Nabriva Therapeutics AG (NASDAQ:NBRV) last announced its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($5.83) by $5.29. The firm had revenue of $1.05 million during the quarter, compared to analysts’ expectations of $1.34 million.
NBRV has been the topic of several research reports. HC Wainwright reissued a “buy” rating on shares of Nabriva Therapeutics AG in a report on Friday, May 12th. Cantor Fitzgerald set a $16.00 target price on Nabriva Therapeutics AG and gave the company a “buy” rating in a report on Thursday, May 11th. Zacks Investment Research raised Nabriva Therapeutics AG from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a report on Saturday, May 27th. ValuEngine raised Nabriva Therapeutics AG from a “sell” rating to a “hold” rating in a report on Saturday, June 24th. Finally, Wedbush reissued an “outperform” rating and issued a $13.00 target price on shares of Nabriva Therapeutics AG in a report on Monday, May 15th. One analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the stock. Nabriva Therapeutics AG has a consensus rating of “Buy” and an average target price of $15.43.
In other news, major shareholder Hbm Healthcare Investments (Ca sold 13,127 shares of the company’s stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $10.94, for a total value of $143,609.38. Following the sale, the insider now directly owns 2,583,229 shares in the company, valued at $28,260,525.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director George Harrison Talbot sold 325 shares of the company’s stock in a transaction on Thursday, May 25th. The shares were sold at an average price of $100.56, for a total value of $32,682.00. Following the completion of the sale, the director now owns 3,854 shares in the company, valued at $387,558.24. The disclosure for this sale can be found here. Insiders sold 242,708 shares of company stock worth $2,646,784 over the last 90 days.
Several hedge funds have recently modified their holdings of NBRV. Renaissance Technologies LLC bought a new stake in shares of Nabriva Therapeutics AG during the fourth quarter valued at about $103,000. Almanack Investment Partners LLC. bought a new stake in shares of Nabriva Therapeutics AG during the first quarter valued at about $1,870,000. Nationwide Fund Advisors bought a new stake in shares of Nabriva Therapeutics AG during the first quarter valued at about $2,074,000. Finally, Wellington Management Group LLP increased its stake in shares of Nabriva Therapeutics AG by 9.9% in the first quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock valued at $25,830,000 after buying an additional 193,951 shares in the last quarter. Institutional investors and hedge funds own 56.65% of the company’s stock.
Shares of Nabriva Therapeutics AG (NASDAQ NBRV) traded down 6.86% on Friday, reaching $9.78. The company’s stock had a trading volume of 16,009 shares. The stock’s market capitalization is $26.61 million. Nabriva Therapeutics AG has a 1-year low of $3.52 and a 1-year high of $12.75. The company has a 50 day moving average of $10.26 and a 200 day moving average of $10.28.
Nabriva Therapeutics AG Company Profile
Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.